Psychosurgery Promoted by NYT: Here We Go, Again
"Only 3 patients were in remission without adverse effects at long-term follow-up."
"Only 3 patients were in remission without adverse effects at long-term follow-up."
Corporate business ethics and investors’ interests have swept aside the humanitarian foundation of American medicine and most of related healthcare, and caring service professions.
…instead of informed patient consent, doctors too often promoted trial treatments as superior to standard approaches, even when there was no supporting evidence.
Dr. Joshua Sharfstein, the FDA’s principal deputy commissioner, acknowledged: “The message here is that there were problems with the integrity of F.D.A.’s decision-making process that have solutions.”
Big Pharma’s defense for its inequitable U.S. pricing is grounded on a Big Lie
Ghostwritten journal reports masquerading as scientifically validated reports are a menace to public health.
Two high ranking FDA officials’ conflicts of interest have led one to resign, the other is under investigation by the Inspector General of the Department of Health and Human Services:
At the July 30, 2009 FDA advisory committee hearing, the only formal presentations at the meeting were a summary of the safety and efficacy data by the sponsor.
Today’s New York Times reports (below) that "court documents provide a paper trail showing that Wyeth contracted with a medical communications company to outline articles, draft them and then solicit top physicians to sign their names, even though many of the doctors contributed little or no writing."
ACRE’s mission is to persuade physicians that MORE rather than less industry involvement in Continuing Medical Education programs is good for patients–much as industry’s "Harry and Louise" ads were aimed at convincing the public that universal healthcare was BAD for them.
Unless the overall treatment and services provided to schizophrenia patients in Finland is unique and especially protective—which the authors do not suggest—their claimed findings of lowered mortality rates for antipsychotic drug users are belied by a consistent body of evidence.
The study, reported in The Journal of the American Medical Association, "found no evidence of an association between the serotonin gene and the risk of depression, no matter what people’s life experience was."